Dark Knight Rising
Rotterdam harbour
In the latest installment of our CAR-T cell mini-series, we take a look on the ‘dark side’ as we switch from liquid to solid tumours.
We have made some great progress in leukemia, lymphomas, and even multiple myeloma while solid tumours have presented a much greater challenge for the field.
There have been some helpful developments over the last few years relevant to this front, however, although when each is seen in isolation, the potential may not be apparent.
Here we look at the bigger picture and highlight important areas, which could lead to some surprising new developments emerging over the next few years…
To continue reading our latest highlights on oncology new product development, including an expert interview plus commentary and analysis BSB subscribers can log-in or you can click to access the content.
This content is restricted to subscribers
